Genprex to Present at Upcoming Investor Conferences
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 21, 2018--Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that company management will present at the following upcoming investor and industry conferences:
About Genprex, Inc. Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at https://twitter.com/genprex and Facebook at https://www.facebook.com/genprexinc/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180821005237/en/
James Heins, 203-682-8251
Stephanie Carrington, 646-277-1282
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS TEXAS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY OTHER HEALTH
SOURCE: Genprex, Inc.
Copyright Business Wire 2018.
PUB: 08/21/2018 08:30 AM/DISC: 08/21/2018 08:30 AM